Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Inclusion Criteria: * Documented RRMM after last treatment. Refractory is defined as meeting 1 or more of the following: Nonresponsive to most recent therapy (stable disease \[SD\] or progressive disease \[PD\]) while on treatment, or Disease progression within 60 days of discontinuation from the most recent therapy. * Eligible to receive Kyprolis per the locally approved label. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Adequate hepatic function within 28 days prior to enrollment: bilirubin \< 1.5 times the upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times the ULN. * Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9 /L within 28 days prior to enrollment. (Screening ANC should be independent of granulocyte- and granulocyte macrophage-colony stimulating factor support for at least 1 week and of pegylated granulocyte stimulating factor for ≥ 2 weeks). * Hemoglobin ≥ 80 g/L within 28 days prior to enrollment. Subjects should not have received red blood cell (RBC) transfusions for at least 7 days prior to obtaining the screening hemoglobin. * Platelet count ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if myeloma involvement in the bone marrow is ≥ 50%) within 28 days prior to enrollment. Subjects should not have received platelet transfusions for at least 7 days prior to obtaining the screening platelet count. * Adequate renal function within 28 days prior to enrollment (either measured or calculated usin…